BRITTANY KUHLENBECK: Open Payments
NPI 1649845066 · OSSIAN, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$489 in 31 payments from 12 companies in 2025. Trend: 2023 $399 · 2024 $650 · 2025 $489
Food & beverage: $489
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $179 |
| AstraZeneca Pharmaceuticals LP | 3 | $54 |
| Exact Sciences Corporation | 2 | $37 |
| Novo Nordisk Inc | 2 | $37 |
| Lilly USA, LLC | 2 | $32 |
| Vanda Pharmaceuticals Inc. | 2 | $31 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $28 |
| GlaxoSmithKline, LLC. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $17 |
Products named: QULIPTA, VRAYLAR, BREZTRI, MOUNJARO, FANAPT, UBRELVY, CAPLYTA, TRELEGY ELLIPTA.
Industry payments across IN — which companies pay providers there.
